Gene Expression Analysis Market is projected to grow from $4.2 billion in 2024 to $6.2 billion by 2029, at a CAGR of 8.1%. This growth is driven by advancements in gene editing technologies such as CRISPR-Cas9 and TALENs, which enhance genome manipulation and gene function studies. The market faces challenges due to high costs of instruments and consumables, but opportunities abound with the increasing focus on single-cell analysis, which offers detailed insights into cellular behavior. North America currently holds the largest market share, supported by significant R&D investments and the presence of key industry players such as Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina, and QIAGEN. The market is segmented into reagents and consumables, instruments, and services, with drug discovery and development being the fastest-growing application. Key players are also expanding their reach through collaborations and new facilities in emerging markets.
Download an Illustrative overview
Browse in-depth TOC on “Gene Expression Analysis Market”
436 – Tables
54 – Figures
369 – Pages
Key Market Players of Gene Expression Analysis Industry:
Key players in the gene expression analysis market are Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories Inc. (US), Illumina Inc (US), QIAGEN (Netherlands), F. Hoffmann-La Roche (Switzerland), Revvity (US), PacBio (US), Agilent Technologies Inc (US), Oxford Gene Technology IP Limited (UK), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc (Japan), 10x Genomics (US), Zymo Research Corporation (US), Twist Bioscience (US), Promega Corporation (US), LGC Limited (UK), CD Genomics (US), NanoString Technologies Inc. (US), BioSpyder, Inc (US), Integrated DNA Technologies, Inc (US) and New England Biolabs (US).
The assays & kits segment accounted for the largest share of reagents & consumables in the gene expression analysis market in 2023.
By reagents & consumables, the gene expression analysis market has been further categorized into assays & kits, enzymes, DNA chips, and others. Assays & kits accounted for the largest share of the gene expression analysis market in 2023. The increasing adoption of high-throughput technologies such as next-generation sequencing (NGS) and microarray analysis has boosted the demand for assays and kits. These technologies generate large amounts of data, and assays and kits help in streamlining the workflow, from sample preparation to data analysis.
The drug discovery & development application segment is expected to grow at a higher rate during the forecast period.
Based on technology, the gene expression analysis market has been segmented into drug discovery & development, clinical diagnostics, and other applications. In 2023, the drug discovery & development segment accounted for the largest share of the gene expression analysis market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. The share share of drug discovery & development application is attributed to gene expression analysis is instrumental in the preclinical and clinical stages of drug development. In preclinical studies, researchers use gene expression profiling to assess the efficacy and safety of potential drug candidates. This helps in selecting the most promising candidates for further development, reducing the time and cost associated with drug discovery.
The pharmaceutical & biotechnology companies segment accounted for the largest share of the end user segment in the gene expression analysis market in 2023.
Based on end user, the gene expression analysis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the gene expression analysis market. As the pharmaceutical & biotechnology companies heavily rely on understanding how genes are expressed in various disease states to identify potential drug targets. Gene expression analysis helps in pinpointing genes that are upregulated or downregulated in diseases, providing valuable insights into disease mechanisms and potential therapeutic interventions.
The North America region accounted for the largest share of the gene expression analysis market in 2023.
The gene expression analysis market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North American region is observing rising investments in the field of drug discovery & development. Moreover, the need for advanced therapies due to the rising rate of chronic diseases such as cancer has contributed to the growth of the gene expression analysis market. The supportive government regulations in North America for the development of mAbs and biosimilars also contribute to market growth.
Gene Expression Analysis Market Dynamics:
Drivers:
- Advancements in gene editing technologies
- Increasing funding initiatives for genomic research
- Growing preference for therapeutic applications
- Declining costs of sequencing technologies
Restraints:
- High cost of instruments & consumables
- Concerns associated with data privacy and security
Opportunities:
- High growth potential across non-clinical applications
- Machine learning and AI
- Growing focus on single-cell analysis
Challenge:
- Extensive timelines for product approval
- Data interpretation challenges
Recent Developments of Gene Expression Analysis Industry:
- In May 2023, Thermo Fisher Scientific and Pfizer collaborated to expand localized access to Next-generation Sequencing-based testing for cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia.
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics to expand its capabilities by inculcating a new generation of rapid PCR systems into its product portfolio.
- In April 2022, Illumina established a new state-of-the-art facility solution center in São Paulo, Brazil, to expand global access to genomics in Latin America. Illumina’s revenue is majorly generated from markets across North America, Europe, the Middle East, and Africa.